DelveInsight’s, “Type 1 Diabetes Pipeline Insight 2023” report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in the Type 1 Diabetes pipeline landscape. It covers the Type 1 Diabetes pipeline drug profiles, including Type 1 Diabetes clinical trials and nonclinical stage products. It also covers the Type 1 Diabetes pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key takeaways from the Type 1 Diabetes Pipeline Report
Explore more about the latest breakthroughs in the Type 1 Diabetes Treatment Landscape @ Type 1 Diabetes Pipeline Outlook
Type 1 Diabetes Overview
Type 1 diabetes (also known as diabetes mellitus) is an autoimmune disease in which immune cells attack and destroy the insulin-producing cells of the pancreas. Type 1 diabetes mellitus (T1DM) is an autoimmune disease that leads to the destruction of insulin-producing pancreatic beta cells. Insulin is an essential anabolic hormone that exerts multiple effects on glucose, lipid, protein, and mineral metabolism, as well as growth.
Recent Developmental Activities in Type 1 Diabetes Treatment Landscape
• In July 2022, Vertex Pharmaceuticals announced that the company has entered into a definitive agreement under which Vertex will acquire ViaCyte, a privately held biotechnology company focused on delivering novel stem cell-derived cell replacement therapies as a functional cure for type 1 diabetes (T1D), for $320 million in cash.
• In June 2022, Vertex Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) lifted the clinical hold placed on the Phase I/II clinical trial of VX-880, an investigational stem cell-derived, fully differentiated pancreatic islet cell replacement therapy for people with type 1 diabetes (T1D) with impaired hypoglycemia awareness and severe hypoglycemia.
• In April 2022, AVM Biotechnology received Small Business Innovation Research (SBIR) award of $1.6m from the National Institute of Diabetes and Digestive Kidney Disease (NIDDK) to study its small molecule, AVM0703, for reversing Type 1 diabetes (T1D). The latest grant will permit the company to carry out further research into using AVM0703 as a single agent and as a combination treatment for reversing recent onset and established T1D.
• In May 2022, Sernova and Evotec are pleased to announce an exclusive global strategic partnership to develop a best-in-class cell therapy treatment for people living with insulin-dependent diabetes. The partnership provides Sernova a global exclusive option to license Evotec’s iPSC-based beta cells for use in treating both type 1 and type 2 diabetes. In addition to entering into the collaboration agreement, Evotec has made a strategic equity investment of €15M and will make a further investment of €5M.
• In March 2022, Jaguar Gene Therapy announced Samsung Ventures, an investment corporation established to promote the development of new technologies, and the JDRF T1D Fund, a venture philanthropy fund devoted to finding and funding the best cure-oriented therapies for Type 1 diabetes (T1D), have invested in the company.
• In January 2022, Remedium Bio announced it has entered into a Sponsored Research Agreement with the University of Massachusetts Boston to complete pre-clinical efficacy studies on Type 1 and Type 2 Diabetes pipeline candidates. The collaboration to evaluate platform technology for the treatment of Diabetes, with translational potential to the broader Remedium pipeline of single-injection potentially disease-modifying gene therapies.
Type 1 Diabetes Emerging Drugs
• Teplizumab: Prevention Bio
• Emricasan: Histogen
• VX-880: Vertex Pharmaceuticals
Discover more about therapy set to grab substantial Type 1 Diabetes Pipeline Landscape @ Type 1 Diabetes Ongoing Clinical Trial Analysis
Type 1 Diabetes Pipeline Therapeutics Analysis
There are approx. 80+ key companies which are developing therapies for Type 1 Diabetes. The companies which have their Type 1 Diabetes drug candidates in the most advanced stage, i.e preregistration include Provention Bio.
DelveInsight’s Type 1 Diabetes Pipeline Report covers around 100+ products under different phases of clinical development-
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Know which Type 1 Diabetes Treatment Drugs are expected to score the touchdown first @ Type 1 Diabetes Treatment Landscape
Scope of the Type 1 Diabetes Pipeline Report
Table of Content
1. Introduction
2. Executive Summary
3. Type 1 Diabetes: Overview
4. Type 1 Diabetes Pipeline Therapeutics
5. Type 1 Diabetes Therapeutic Assessment
6. Type 1 Diabetes- DelveInsight’s Analytical Perspective
7. Late Stage Products (Preregistration)
8. Teplizumab: Provention Bio
9. Mid Stage Products (Phase II)
10. TTP 399: Novo Nordisk
11. Early Stage Products (Phase I/II)
12. SBP 101: Takeda Oncology
13. Early Stage Products (Phase I)
14. Eflornithine oral: Panbela Therapeutics
15. Inactive Products
16. Type 1 Diabetes Key Companies
17. Type 1 Diabetes Key Products
18. Type 1 Diabetes- Unmet Needs
19. Type 1 Diabetes- Market Drivers and Barriers
20. Type 1 Diabetes- Future Perspectives and Conclusion
21. Type 1 Diabetes Analyst Views
22. Type 1 Diabetes Key Companies
23. Appendix
For further information on the Type 1 Diabetes Pipeline Therapeutics, reach out Type 1 Diabetes Market Drivers and Barriers
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsightContact Person: Yash BhardwajEmail: Send EmailPhone: 09193216187Address:304 S. Jones Blvd #2432, City: Las VegasState: United StatesCountry: IndiaWebsite: https://www.delveinsight.com/
